Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07082829 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 24, 2025 (before its estimated June 15, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 1 to 3
    • Primary and study completion dates: Dec 31, 2025 to Jun 15, 2026
    • Eligibility criteria revised
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Characterize the safety, tolerability and pharmacokinetics of ORX142 following single and multiple doses.
Trial Details
NCT Number NCT07082829
Lead Sponsor Centessa Pharmaceuticals (UK) Limited
Conditions
(from sponsor)		 Excessive Daytime Sleepiness
Related terms Disorders of Excessive Somnolence
Enrollment 208 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov